ADGMAdagio Medical Holdings, Inc.
Sign up free
Thesis

Pivotal data strong, PMA filed, but ~$8M cash covers barely one quarter before an expected Q4 2026 approval decision

Updated 33d ago

Adagio Medical is a clinical-stage medical device company developing a catheter-based ablation treatment for abnormal heart rhythms that is not yet approved.

With $8M cash and a $6.7M quarterly burn, Adagio is racing a Q4 2026 FDA PMA decision on fumes: the company may not survive to collect revenue even if approved. FULCRUM-VT met its primary endpoints in 209 patients, showing 84% freedom from ICD shock and a 2.4% major adverse event rate that compares favorably to radiofrequency and pulsed-field ablation, supporting a credible safety-efficacy profile. The thesis resolves on whether FDA grants PMA before cash runs out and the company can finance a commercial launch, with single-arm trial design the key approval-path risk.

Status
Challenged
Conviction

Current Thesis Drivers

  • FULCRUM-VT met primary endpoints: 84% ICD-shock-free, 2.4% MAE
  • PMA filed May 2026; Breakthrough Device Designation granted
  • Approvability unresolved — single-arm data back at FDA for PMA review
  • Cash ~$8M; burn $6.7M/qtr — sub-one-quarter runway

What could change the thesis?

  • Q4 2026 PMA decision: approval unlocks revenue, denial or delay breaks the company
  • Financing event: bridge preserves optionality, dilutive raise or failure accelerates insolvency
  • vCLAS Ultra enrollment: expanded label strengthens franchise, slow enrollment delays differentiation

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

2 programs · 8 catalysts

Competitive landscape

2 peers tracked

Stress Test